Aprea Therapeutics (NASDAQ:APRE) Issues Earnings Results, Beats Expectations By $0.05 EPS

Aprea Therapeutics (NASDAQ:APRE) announced its quarterly earnings results on Monday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05, Yahoo Finance reports. Aprea Therapeutics had a negative return on equity of 56.78% and a negative net margin of 1,317.82%. The company had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.10 million.

Aprea Therapeutics Trading Down 1.5 %

Shares of APRE opened at $3.25 on Wednesday. The firm has a market cap of $17.65 million, a PE ratio of -0.99 and a beta of 1.04. The firm has a fifty day simple moving average of $3.95 and a two-hundred day simple moving average of $5.26. Aprea Therapeutics has a 1-year low of $3.20 and a 1-year high of $8.85.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on APRE. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Monday.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.